ExploreWatchlistsPricing
  1. JP-listed companies
  2. Chiome Bioscience Inc.
  3. Financials
  4. Stockholders' equity

Chiome Bioscience Inc. (4583)

Market cap
¥7.1B
P/E ratio
Develops antibody drugs for cancer and other diseases using its ADLib® System technology, while providing antibody development services to pharmaceutical companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Dec 31, 20251,122-41.57%
Dec 31, 20241,920+65.87%
Dec 31, 20231,158-35.35%
Dec 31, 20221,791-5.40%
Dec 31, 20211,893-39.13%
Dec 31, 20203,110+18.63%
Dec 31, 20192,622-2.06%
Dec 31, 20182,677-36.53%
Dec 31, 20174,218-7.61%
Dec 31, 20164,565+0.02%
Dec 31, 20154,564-21.51%
Dec 31, 20145,815+28.52%
Mar 31, 20144,525

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat